Summary
Global Markets Direct’s, ‘Head And Neck Cancer - Pipeline Review, H1 2016’, provides an overview of the Head And Neck Cancer pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Head And Neck Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Head And Neck Cancer and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Head And Neck Cancer
- The report reviews pipeline therapeutics for Head And Neck Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Head And Neck Cancer therapeutics and enlists all their major and minor projects
- The report assesses Head And Neck Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Head And Neck Cancer
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Head And Neck Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Head And Neck Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
4SC AG
AB Science SA
AbbVie Inc.
Acceleron Pharma, Inc.
Advaxis, Inc.
Alchemia Limited
Altor BioScience Corporation
Ambrx, Inc.
Amgen Inc.
ANP Technologies, Inc.
arGEN-X BV
ArQule, Inc.
Astellas Pharma Inc.
AstraZeneca Plc
Atara Biotherapeutics, Inc.
ATLAB Pharma SAS
AVEO Pharmaceuticals, Inc.
Bayer AG
Betta Pharmaceuticals Co. Ltd.
Bexion Pharmaceuticals, LLC.
Bio-Path Holdings, Inc.
BioDiem Ltd
Biomics Biotechnologies Co., Ltd.
Bionovis SA
Biotest AG
Boehringer Ingelheim GmbH
Boston Biomedical, Inc.
Bristol-Myers Squibb Company
CEL-SCI Corporation
Celgene Corporation
Cell Medica Limited
Cellceutix Corporation
Celldex Therapeutics, Inc.
Celltrion, Inc.
Centrose LLC
Corvus Pharmaceuticals, Inc.
Cristal Therapeutics B.V.
Critical Outcome Technologies Inc.
CTI BioPharma Corp.
CytomX Therapeutics, Inc.
Daiichi Sankyo Company, Limited
Debiopharm International SA
Eisai Co., Ltd.
Eli Lilly and Company
EntreChem, S.L.
Etubics Corporation
Eureka Therapeutics, Inc.
F. Hoffmann-La Roche Ltd.
Five Prime Therapeutics, Inc.
G&E Herbal Biotechnology Co., Ltd.
Genelux Corporation
Genentech, Inc.
Genexine, Inc.
Genmab A/S
Genticel S.A.
GlaxoSmithKline Plc
Gliknik, Inc.
Glycotope GmbH
Green Cross Corporation
Hanmi Pharmaceuticals, Co. Ltd.
HEC Pharm Co., Ltd.
Horizon Pharma Plc
Hutchison MediPharma Limited
Ignyta, Inc.
Immune Design Corp.
Immunomedics, Inc.
Immunovaccine, Inc.
Immunovative Therapies, Ltd.
Incuron, LLC
Incyte Corporation
Innate Pharma S.A.
Inovio Pharmaceuticals, Inc.
InteRNA Technologies B.V.
IRX Therapeutics, Inc.
ISA Pharmaceuticals B.V.
ISU ABXIS Co.,Ltd.
Jiangsu Kanion Pharmaceutical Co., Ltd.
Johnson & Johnson
Kite Pharma, Inc.
Kolltan Pharmaceuticals, Inc.
Laboratoires Pierre Fabre SA
Loxo Oncology, Inc.
Lytix Biopharma AS
Mabion SA
Mabtech Limited
MacroGenics, Inc.
Marsala Biotech Inc.
Meabco A/S
MedImmune, LLC
Merck & Co., Inc.
Merck KGaA
Merrimack Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc.
Mirati Therapeutics Inc.
Molecular Partners AG
Molplex Ltd.
Multimmune GmbH
NanoCarrier Co., Ltd.
Natco Pharma Limited
Northwest Biotherapeutics, Inc.
Novartis AG
Omnitura Therapeutics Inc.
Oncobiologics, Inc.
Oncolys BioPharma Inc.
Oncolytics Biotech Inc.
Onconova Therapeutics, Inc.
OncoSec Medical Incorporated
Ono Pharmaceutical Co., Ltd.
Orbis Biosciences, Inc.
Oryx GmbH & Co. KG
Otsuka Holdings Co., Ltd.
OXiGENE, Inc.
Panacea Biotec Limited
PCI Biotech Holding ASA
Pfizer Inc.
Pharma Mar, S.A.
Pharmacyclics, Inc.
Philogen S.p.A.
Pique Therapeutics
Plexxikon Inc.
PNP Therapeutics, Inc.
Profectus BioSciences, Inc.
Sanofi
Sapvax
Sareum Holdings Plc
Selecta Biosciences, Inc.
Shanghai Henlius Biotech Co., Ltd.
Shenzen SiBiono GeneTech Co., Ltd.
Shionogi & Co., Ltd.
Silence Therapeutics Plc
Sillajen Biotherapeutics
Sinil Pharmaceutical Co., Ltd
Sorrento Therapeutics, Inc.
SuviCa Inc.
Symphogen A/S
Synta Pharmaceuticals Corp.
Taiwan Liposome Company, Ltd.
Takara Bio Inc.
Takis S.r.l.
Teva Pharmaceutical Industries Ltd.
Theravectys SA
Threshold Pharmaceuticals, Inc.
Tolero Pharmaceuticals, Inc.
UbiVac, LLC
Vaccibody AS
VasGene Therapeutics, Inc.
VentiRx Pharmaceuticals, Inc.
Virttu Biologics Limited
VLPbio
VM Discovery, Inc.
Vyriad
'
Table of Contents
Table of Contents 2
Introduction 8
Head and neck Cancer Overview 9
Therapeutics Development 10
Head and neck Cancer - Therapeutics under Development by Companies 12
Head and neck Cancer - Therapeutics under Investigation by Universities/Institutes 25
Head and neck Cancer - Pipeline Products Glance 27
Head and neck Cancer - Products under Development by Companies 31
Head and neck Cancer - Products under Investigation by Universities/Institutes 50
Head and neck Cancer - Companies Involved in Therapeutics Development 53
Head and neck Cancer - Therapeutics Assessment 204
Drug Profiles 241
Head and neck Cancer - Recent Pipeline Updates 758
Head and neck Cancer - Dormant Projects 1073
Head and neck Cancer - Discontinued Products 1086
Head and neck Cancer - Product Development Milestones 1089
Appendix 1096
List of Tables
Number of Products under Development for Head and neck Cancer, H1 2016 40
Number of Products under Development for Head and neck Cancer - Comparative Analysis, H1 2016 41
Number of Products under Development by Companies, H1 2016 43
Number of Products under Development by Companies, H1 2016 (Contd..1) 44
Number of Products under Development by Companies, H1 2016 (Contd..2) 45
Number of Products under Development by Companies, H1 2016 (Contd..3) 46
Number of Products under Development by Companies, H1 2016 (Contd..4) 47
Number of Products under Development by Companies, H1 2016 (Contd..5) 48
Number of Products under Development by Companies, H1 2016 (Contd..6) 49
Number of Products under Development by Companies, H1 2016 (Contd..7) 50
Number of Products under Development by Companies, H1 2016 (Contd..8) 51
Number of Products under Development by Companies, H1 2016 (Contd..9) 52
Number of Products under Development by Companies, H1 2016 (Contd..10) 53
Number of Products under Development by Companies, H1 2016 (Contd..11) 54
Number of Products under Investigation by Universities/Institutes, H1 2016 55
Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 56
Comparative Analysis by Late Stage Development, H1 2016 57
Comparative Analysis by Clinical Stage Development, H1 2016 58
Comparative Analysis by Early Stage Development, H1 2016 59
Comparative Analysis by Unknown Stage Development, H1 2016 60
Products under Development by Companies, H1 2016 61
Products under Development by Companies, H1 2016 (Contd..1) 62
Products under Development by Companies, H1 2016 (Contd..2) 63
Products under Development by Companies, H1 2016 (Contd..3) 64
Products under Development by Companies, H1 2016 (Contd..4) 65
Products under Development by Companies, H1 2016 (Contd..5) 66
Products under Development by Companies, H1 2016 (Contd..6) 67
Products under Development by Companies, H1 2016 (Contd..7) 68
Products under Development by Companies, H1 2016 (Contd..8) 69
Products under Development by Companies, H1 2016 (Contd..9) 70
Products under Development by Companies, H1 2016 (Contd..10) 71
Products under Development by Companies, H1 2016 (Contd..11) 72
Products under Development by Companies, H1 2016 (Contd..12) 73
Products under Development by Companies, H1 2016 (Contd..13) 74
Products under Development by Companies, H1 2016 (Contd..14) 75
Products under Development by Companies, H1 2016 (Contd..15) 76
Products under Development by Companies, H1 2016 (Contd..16) 77
Products under Development by Companies, H1 2016 (Contd..17) 78
Products under Development by Companies, H1 2016 (Contd..18) 79
Products under Investigation by Universities/Institutes, H1 2016 80
Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 81
Products under Investigation by Universities/Institutes, H1 2016 (Contd..2) 82
Head and neck Cancer - Pipeline by 4SC AG, H1 2016 83
Head and neck Cancer - Pipeline by AB Science SA, H1 2016 84
Head and neck Cancer - Pipeline by AbbVie Inc., H1 2016 85
Head and neck Cancer - Pipeline by Acceleron Pharma, Inc., H1 2016 86
Head and neck Cancer - Pipeline by Advaxis, Inc., H1 2016 87
Head and neck Cancer - Pipeline by Alchemia Limited, H1 2016 88
Head and neck Cancer - Pipeline by Altor BioScience Corporation, H1 2016 89
Head and neck Cancer - Pipeline by Ambrx, Inc., H1 2016 90
Head and neck Cancer - Pipeline by Amgen Inc., H1 2016 91
Head and neck Cancer - Pipeline by ANP Technologies, Inc., H1 2016 92
Head and neck Cancer - Pipeline by arGEN-X BV, H1 2016 93
Head and neck Cancer - Pipeline by ArQule, Inc., H1 2016 94
Head and neck Cancer - Pipeline by Astellas Pharma Inc., H1 2016 95
Head and neck Cancer - Pipeline by AstraZeneca Plc, H1 2016 96
Head and neck Cancer - Pipeline by Atara Biotherapeutics, Inc., H1 2016 97
Head and neck Cancer - Pipeline by ATLAB Pharma SAS, H1 2016 98
Head and neck Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H1 2016 99
Head and neck Cancer - Pipeline by Bayer AG, H1 2016 100
Head and neck Cancer - Pipeline by Betta Pharmaceuticals Co. Ltd., H1 2016 101
Head and neck Cancer - Pipeline by Bexion Pharmaceuticals, LLC., H1 2016 102
Head and neck Cancer - Pipeline by Bio-Path Holdings, Inc., H1 2016 103
Head and neck Cancer - Pipeline by BioDiem Ltd, H1 2016 104
Head and neck Cancer - Pipeline by Biomics Biotechnologies Co., Ltd., H1 2016 105
Head and neck Cancer - Pipeline by Bionovis SA, H1 2016 106
Head and neck Cancer - Pipeline by Biotest AG, H1 2016 107
Head and neck Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2016 108
Head and neck Cancer - Pipeline by Boston Biomedical, Inc., H1 2016 109
Head and neck Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2016 110
Head and neck Cancer - Pipeline by CEL-SCI Corporation, H1 2016 111
Head and neck Cancer - Pipeline by Celgene Corporation, H1 2016 112
Head and neck Cancer - Pipeline by Cell Medica Limited, H1 2016 113
Head and neck Cancer - Pipeline by Cellceutix Corporation, H1 2016 114
Head and neck Cancer - Pipeline by Celldex Therapeutics, Inc., H1 2016 115
Head and neck Cancer - Pipeline by Celltrion, Inc., H1 2016 116
Head and neck Cancer - Pipeline by Centrose LLC, H1 2016 117
Head and neck Cancer - Pipeline by Corvus Pharmaceuticals, Inc., H1 2016 118
Head and neck Cancer - Pipeline by Cristal Therapeutics B.V., H1 2016 119
Head and neck Cancer - Pipeline by Critical Outcome Technologies Inc., H1 2016 120
Head and neck Cancer - Pipeline by CTI BioPharma Corp., H1 2016 121
Head and neck Cancer - Pipeline by CytomX Therapeutics, Inc., H1 2016 122
Head and neck Cancer - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 123
Head and neck Cancer - Pipeline by Debiopharm International SA , H1 2016 124
Head and neck Cancer - Pipeline by Eisai Co., Ltd., H1 2016 125
Head and neck Cancer - Pipeline by Eli Lilly and Company, H1 2016 126
Head and neck Cancer - Pipeline by EntreChem, S.L., H1 2016 127
Head and neck Cancer - Pipeline by Etubics Corporation, H1 2016 128
Head and neck Cancer - Pipeline by Eureka Therapeutics, Inc., H1 2016 129
Head and neck Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 130
Head and neck Cancer - Pipeline by Five Prime Therapeutics, Inc., H1 2016 131
Head and neck Cancer - Pipeline by G&E Herbal Biotechnology Co., Ltd., H1 2016 132
Head and neck Cancer - Pipeline by Genelux Corporation, H1 2016 133
Head and neck Cancer - Pipeline by Genentech, Inc., H1 2016 134
Head and neck Cancer - Pipeline by Genexine, Inc., H1 2016 135
Head and neck Cancer - Pipeline by Genmab A/S, H1 2016 136
Head and neck Cancer - Pipeline by Genticel S.A., H1 2016 137
Head and neck Cancer - Pipeline by GlaxoSmithKline Plc, H1 2016 138
Head and neck Cancer - Pipeline by Gliknik, Inc., H1 2016 139
Head and neck Cancer - Pipeline by Glycotope GmbH, H1 2016 140
Head and neck Cancer - Pipeline by Green Cross Corporation, H1 2016 141
Head and neck Cancer - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2016 142
Head and neck Cancer - Pipeline by HEC Pharm Co., Ltd., H1 2016 143
Head and neck Cancer - Pipeline by Horizon Pharma Plc, H1 2016 144
Head and neck Cancer - Pipeline by Hutchison MediPharma Limited, H1 2016 145
Head and neck Cancer - Pipeline by Ignyta, Inc., H1 2016 146
Head and neck Cancer - Pipeline by Immune Design Corp., H1 2016 147
Head and neck Cancer - Pipeline by Immunomedics, Inc., H1 2016 148
Head and neck Cancer - Pipeline by Immunovaccine, Inc., H1 2016 149
Head and neck Cancer - Pipeline by Immunovative Therapies, Ltd., H1 2016 150
Head and neck Cancer - Pipeline by Incuron, LLC, H1 2016 151
Head and neck Cancer - Pipeline by Incyte Corporation, H1 2016 152
Head and neck Cancer - Pipeline by Innate Pharma S.A., H1 2016 153
Head and neck Cancer - Pipeline by Inovio Pharmaceuticals, Inc., H1 2016 154
Head and neck Cancer - Pipeline by InteRNA Technologies B.V., H1 2016 155
Head and neck Cancer - Pipeline by IRX Therapeutics, Inc., H1 2016 156
Head and neck Cancer - Pipeline by ISA Pharmaceuticals B.V., H1 2016 157
Head and neck Cancer - Pipeline by ISU ABXIS Co.,Ltd., H1 2016 158
Head and neck Cancer - Pipeline by Jiangsu Kanion Pharmaceutical Co., Ltd., H1 2016 159
Head and neck Cancer - Pipeline by Johnson & Johnson, H1 2016 160
Head and neck Cancer - Pipeline by Kite Pharma, Inc., H1 2016 161
Head and neck Cancer - Pipeline by Kolltan Pharmaceuticals, Inc., H1 2016 162
Head and neck Cancer - Pipeline by Laboratoires Pierre Fabre SA, H1 2016 163
Head and neck Cancer - Pipeline by Loxo Oncology, Inc., H1 2016 164
Head and neck Cancer - Pipeline by Lytix Biopharma AS, H1 2016 165
Head and neck Cancer - Pipeline by Mabion SA, H1 2016 166
Head and neck Cancer - Pipeline by Mabtech Limited, H1 2016 167
Head and neck Cancer - Pipeline by MacroGenics, Inc., H1 2016 168
Head and neck Cancer - Pipeline by Marsala Biotech Inc., H1 2016 169
Head and neck Cancer - Pipeline by Meabco A/S, H1 2016 170
Head and neck Cancer - Pipeline by MedImmune, LLC, H1 2016 171
Head and neck Cancer - Pipeline by Merck & Co., Inc., H1 2016 172
Head and neck Cancer - Pipeline by Merck KGaA, H1 2016 173
Head and neck Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2016 174
Head and neck Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016 175
Head and neck Cancer - Pipeline by Mirati Therapeutics Inc., H1 2016 176
Head and neck Cancer - Pipeline by Molecular Partners AG, H1 2016 177
Head and neck Cancer - Pipeline by Molplex Ltd., H1 2016 178
Head and neck Cancer - Pipeline by Multimmune GmbH, H1 2016 179
Head and neck Cancer - Pipeline by NanoCarrier Co., Ltd., H1 2016 180
Head and neck Cancer - Pipeline by Natco Pharma Limited, H1 2016 181
Head and neck Cancer - Pipeline by Northwest Biotherapeutics, Inc., H1 2016 182
Head and neck Cancer - Pipeline by Novartis AG, H1 2016 183
Head and neck Cancer - Pipeline by Omnitura Therapeutics Inc., H1 2016 184
Head and neck Cancer - Pipeline by Oncobiologics, Inc., H1 2016 185
Head and neck Cancer - Pipeline by Oncolys BioPharma Inc., H1 2016 186
Head and neck Cancer - Pipeline by Oncolytics Biotech Inc., H1 2016 187
Head and neck Cancer - Pipeline by Onconova Therapeutics, Inc., H1 2016 188
Head and neck Cancer - Pipeline by OncoSec Medical Incorporated, H1 2016 189
Head and neck Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 190
Head and neck Cancer - Pipeline by Orbis Biosciences, Inc., H1 2016 191
Head and neck Cancer - Pipeline by Oryx GmbH & Co. KG, H1 2016 192
Head and neck Cancer - Pipeline by Otsuka Holdings Co., Ltd., H1 2016 193
Head and neck Cancer - Pipeline by OXiGENE, Inc., H1 2016 194
Head and neck Cancer - Pipeline by Panacea Biotec Limited, H1 2016 195
Head and neck Cancer - Pipeline by PCI Biotech Holding ASA, H1 2016 196
Head and neck Cancer - Pipeline by Pfizer Inc., H1 2016 197
Head and neck Cancer - Pipeline by Pharma Mar, S.A., H1 2016 198
Head and neck Cancer - Pipeline by Pharmacyclics, Inc., H1 2016 199
Head and neck Cancer - Pipeline by Philogen S.p.A., H1 2016 200
Head and neck Cancer - Pipeline by Pique Therapeutics, H1 2016 201
Head and neck Cancer - Pipeline by Plexxikon Inc., H1 2016 202
Head and neck Cancer - Pipeline by PNP Therapeutics, Inc., H1 2016 203
Head and neck Cancer - Pipeline by Profectus BioSciences, Inc., H1 2016 204
Head and neck Cancer - Pipeline by Sanofi, H1 2016 205
Head and neck Cancer - Pipeline by Sapvax, H1 2016 206
Head and neck Cancer - Pipeline by Sareum Holdings Plc, H1 2016 207
Head and neck Cancer - Pipeline by Selecta Biosciences, Inc., H1 2016 208
Head and neck Cancer - Pipeline by Shanghai Henlius Biotech Co., Ltd., H1 2016 209
Head and neck Cancer - Pipeline by Shenzen SiBiono GeneTech Co., Ltd., H1 2016 210
Head and neck Cancer - Pipeline by Shionogi & Co., Ltd., H1 2016 211
Head and neck Cancer - Pipeline by Silence Therapeutics Plc, H1 2016 212
Head and neck Cancer - Pipeline by Sillajen Biotherapeutics, H1 2016 213
Head and neck Cancer - Pipeline by Sinil Pharmaceutical Co., Ltd, H1 2016 214
Head and neck Cancer - Pipeline by Sorrento Therapeutics, Inc., H1 2016 215
Head and neck Cancer - Pipeline by SuviCa Inc., H1 2016 216
Head and neck Cancer - Pipeline by Symphogen A/S, H1 2016 217
Head and neck Cancer - Pipeline by Synta Pharmaceuticals Corp., H1 2016 218
Head and neck Cancer - Pipeline by Taiwan Liposome Company, Ltd., H1 2016 219
Head and neck Cancer - Pipeline by Takara Bio Inc., H1 2016 220
Head and neck Cancer - Pipeline by Takis S.r.l., H1 2016 221
Head and neck Cancer - Pipeline by Teva Pharmaceutical Industries Ltd., H1 2016 222
Head and neck Cancer - Pipeline by Theravectys SA, H1 2016 223
Head and neck Cancer - Pipeline by Threshold Pharmaceuticals, Inc., H1 2016 224
Head and neck Cancer - Pipeline by Tolero Pharmaceuticals, Inc., H1 2016 225
Head and neck Cancer - Pipeline by UbiVac, LLC, H1 2016 226
Head and neck Cancer - Pipeline by Vaccibody AS, H1 2016 227
Head and neck Cancer - Pipeline by VasGene Therapeutics, Inc., H1 2016 228
Head and neck Cancer - Pipeline by VentiRx Pharmaceuticals, Inc., H1 2016 229
Head and neck Cancer - Pipeline by Virttu Biologics Limited, H1 2016 230
Head and neck Cancer - Pipeline by VLPbio, H1 2016 231
Head and neck Cancer - Pipeline by VM Discovery, Inc., H1 2016 232
Head and neck Cancer - Pipeline by Vyriad, H1 2016 233
Assessment by Monotherapy Products, H1 2016 234
Assessment by Combination Products, H1 2016 235
Number of Products by Stage and Target, H1 2016 237
Number of Products by Stage and Mechanism of Action, H1 2016 255
Number of Products by Stage and Route of Administration, H1 2016 268
Number of Products by Stage and Molecule Type, H1 2016 270
Head and neck Cancer Therapeutics - Recent Pipeline Updates, H1 2016 788
Head and neck Cancer - Dormant Projects, H1 2016 1103
Head and neck Cancer - Dormant Projects (Contd..1), H1 2016 1104
Head and neck Cancer - Dormant Projects (Contd..2), H1 2016 1105
Head and neck Cancer - Dormant Projects (Contd..3), H1 2016 1106
Head and neck Cancer - Dormant Projects (Contd..4), H1 2016 1107
Head and neck Cancer - Dormant Projects (Contd..5), H1 2016 1108
Head and neck Cancer - Dormant Projects (Contd..6), H1 2016 1109
Head and neck Cancer - Dormant Projects (Contd..7), H1 2016 1110
Head and neck Cancer - Dormant Projects (Contd..8), H1 2016 1111
Head and neck Cancer - Dormant Projects (Contd..9), H1 2016 1112
Head and neck Cancer - Dormant Projects (Contd..10), H1 2016 1113
Head and neck Cancer - Dormant Projects (Contd..11), H1 2016 1114
Head and neck Cancer - Dormant Projects (Contd..12), H1 2016 1115
Head and neck Cancer - Discontinued Products, H1 2016 1116
Head and neck Cancer - Discontinued Products (Contd..1), H1 2016 1117
Head and neck Cancer - Discontinued Products (Contd..2), H1 2016 1118
List of Figures
Number of Products under Development for Head and neck Cancer, H1 2016 40
Number of Products under Development for Head and neck Cancer - Comparative Analysis, H1 2016 41
Number of Products under Development by Companies, H1 2016 42
Number of Products under Investigation by Universities/Institutes, H1 2016 55
Comparative Analysis by Late Stage Development, H1 2016 57
Comparative Analysis by Clinical Stage Development, H1 2016 58
Comparative Analysis by Early Stage Products, H1 2016 59
Assessment by Monotherapy Products, H1 2016 234
Assessment by Combination Products, H1 2016 235
Number of Products by Top 10 Targets, H1 2016 236
Number of Products by Stage and Top 10 Targets, H1 2016 236
Number of Products by Top 10 Mechanism of Actions, H1 2016 254
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 254
Number of Products by Top 10 Routes of Administration, H1 2016 267
Number of Products by Stage and Top 10 Routes of Administration, H1 2016 267
Number of Products by Top 10 Molecule Types, H1 2016 269
Number of Products by Stage and Top 10 Molecule Types, H1 2016 269
